Cargando…

Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype

OBJECTIVE: Determine whether a treatment effect of ibudilast on brain atrophy rate differs between participants with primary (PPMS) and secondary (SPMS) progressive multiple sclerosis. BACKGROUND: Progressive forms of MS are both associated with continuous disability progression. Whether PPMS and SP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goodman, Andrew D., Fedler, Janel K., Yankey, Jon, Klingner, Elizabeth A., Ecklund, Dixie J., Goebel, Christopher V., Bermel, Robert A., Chase, Marianne, Coffey, Christopher S., Klawiter, Eric C., Naismith, Robert T., Fox, Robert J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818089/ https://www.ncbi.nlm.nih.gov/pubmed/33460301 http://dx.doi.org/10.1002/acn3.51251

Ejemplares similares

Influence of equipment changes on MRI measures of brain atrophy and brain microstructure in a placebo-controlled trial of ibudilast in progressive multiple sclerosis
por: Sakaie, Ken, et al.
Publicado: (2021)

Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial
por: Babu, Suma, et al.
Publicado: (2021)

Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF)
por: Ha, Wendy, et al.
Publicado: (2019)

Role of phosphodiesterase inhibitor Ibudilast in morphine-induced hippocampal injury
por: Zhaleh, Mohsen, et al.
Publicado: (2014)

The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson’s disease
por: Schwenkgrub, Joanna, et al.
Publicado: (2017)

Signal Transduction of Improving Effects of Ibudilast on Methamphetamine Induced Cell Death
por: Tahvilian, Reza, et al.
Publicado: (2019)

Prevalence of Headache Days and Disability 3 Years After Participation in the Childhood and Adolescent Migraine Prevention Medication Trial
por: Powers, Scott W., et al.
Publicado: (2021)

Ibudilast Mitigates Delayed Bone Healing Caused by Lipopolysaccharide by Altering Osteoblast and Osteoclast Activity
por: Chang, Yuhan, et al.
Publicado: (2021)

Ibudilast for alcohol use disorder: study protocol for a phase II randomized clinical trial
por: Burnette, Elizabeth M., et al.
Publicado: (2020)

Emerging Potential of the Phosphodiesterase (PDE) Inhibitor Ibudilast for Neurodegenerative Diseases: An Update on Preclinical and Clinical Evidence
por: Angelopoulou, Efthalia, et al.
Publicado: (2022)

Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial
por: Grodin, Erica N., et al.
Publicado: (2021)

Outcome Measures in Multiple Sclerosis
por: Bermel, Robert, et al.
Publicado: (2014)

Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model
por: Kagitani-Shimono, Kuriko, et al.
Publicado: (2005)

The relationship between cognition, education, and employment in multiple sclerosis patients
por: Conway, Devon S, et al.
Publicado: (2022)

Ibudilast, a Pharmacologic Phosphodiesterase Inhibitor, Prevents Human Immunodeficiency Virus-1 Tat-Mediated Activation of Microglial Cells
por: Kiebala, Michelle, et al.
Publicado: (2011)

Ibudilast, a Phosphodiesterase-4 Inhibitor, Ameliorates Acute Respiratory Distress Syndrome in Neonatal Mice by Alleviating Inflammation and Apoptosis
por: Yang, Dongjie, et al.
Publicado: (2020)

A double-blind, randomized, placebo-controlled pilot trial to determine the efficacy and safety of ibudilast, a potential glial attenuator, in chronic migraine
por: Kwok, Yuen H, et al.
Publicado: (2016)

Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions
por: Cohen, Jeffrey A, et al.
Publicado: (2022)

297 The Acute to Chronic Pain Signatures Program (A2CPS): Conceptual Design and Protocol Implementation of a Multi-site Observational Study Assessing Risk and Resilience Biomarkers
por: Berardi, Giovanni, et al.
Publicado: (2022)

Ibudilast Attenuates Folic Acid–Induced Acute Kidney Injury by Blocking Pyroptosis Through TLR4-Mediated NF-κB and MAPK Signaling Pathways
por: Li, Xue, et al.
Publicado: (2021)

The association between handedness and clinicodemographic characteristics in people with multiple sclerosis: a brief report
por: Shirani, Afsaneh, et al.
Publicado: (2019)

Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial
por: Griguer, Corinne E, et al.
Publicado: (2021)

The Calm Between Storms: Serum Biomarkers in Assessing Interattack Astrocytopathy in Neuromyelitis Optica Spectrum Disorder
por: Goldschmidt, Carolyn, et al.
Publicado: (2021)

Providing Person-Centered Care via Telemedicine in the Era of COVID-19 in Multiple Sclerosis
por: Abbatemarco, Justin R, et al.
Publicado: (2021)

Prospects of siponimod in secondary progressive multiple sclerosis
por: McGinley, Marisa, et al.
Publicado: (2018)

Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures
por: Alvarez, Enrique, et al.
Publicado: (2015)

Gait asymmetry, and bilateral coordination of gait during a six-minute walk test in persons with multiple sclerosis
por: Plotnik, Meir, et al.
Publicado: (2020)

Obtaining Patient Priorities in a Multiple Sclerosis Comprehensive Care Center: Beyond Patient-Reported Outcomes
por: Miller, Deborah M, et al.
Publicado: (2019)

Turning is an important marker of balance confidence and walking limitation in persons with multiple sclerosis
por: Adusumilli, Gautam, et al.
Publicado: (2018)

LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts
por: Merchant, Kalpana M., et al.
Publicado: (2023)

How patients with multiple sclerosis acquire disability
por: Lublin, Fred D, et al.
Publicado: (2022)

Multiple sclerosis diagnosis: Knowledge gaps and opportunities for educational intervention in neurologists in the United States
por: Solomon, Andrew J, et al.
Publicado: (2021)

Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial
por: Weinstock-Guttman, Bianca, et al.
Publicado: (2021)

Detection of grey matter microstructural substrates of neurodegeneration in multiple sclerosis
por: Krijnen, Eva A, et al.
Publicado: (2023)

Clinical features and outcomes of COVID-19 despite SARS-CoV-2 vaccination in people with multiple sclerosis
por: Rose, Deja R, et al.
Publicado: (2021)

Axonal and myelin changes and their inter-relationship in the optic radiations in people with multiple sclerosis
por: Krijnen, Eva A., et al.
Publicado: (2023)

Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
por: Irwin, David J., et al.
Publicado: (2020)

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up
por: Hersh, Carrie M, et al.
Publicado: (2017)

Pleural mesothelioma – case report
por: Klawiter, Anna, et al.
Publicado: (2010)

Are There Clinical Differences in Limited Systemic Sclerosis according to Extension of Skin Involvement?
por: Scolnik, Marina, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_sibeib0mdp54dmik1davgqe8n9